NCT01316302

12-Week Study of Pristiq (Desvenlafaxine) Social Anxiety Disorder

A 12-Week Double-Blind, Placebo-Controlled, Flexible-Dose Trial of Pristiq® (Desvenlafaxine) Extended-Release Tablets in Generalized Social Anxiety Disorder

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 63 (actual)
• Sponsor: The Medical Research Network · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study is designed to evaluate the efficacy and safety of Pristiq® in treatment of the symptoms of Generalized Social Anxiety Disorder (SAD).

Detailed description

Social Anxiety Disorder (SAD) is recognized as a prevalent, chronic and disabling condition. Lifetime prevalence has been estimated at 13% in the National Comorbidity Survey. There is good reason to think that Pristiq® would be effective in Social Anxiety Disorder. Effexor XR, which is mechanistically similar to Pristiq®, was found effective for subjects with Generalized Social Anxiety Disorder in all five of the placebo controlled trials in which it was studied.

Conditions

• Social Anxiety Disorder

Interventions

Type	Name	Description
DRUG	Pristiq	Flexible dose, 50-100mg QD, for 12 weeks.
DRUG	Placebo	Matching placebo, taken QD for 12 weeks.

Timeline

• Start date: 2011-04-01
• Primary completion: 2012-11-01
• Completion: 2012-12-01
• First posted: 2011-03-16
• Last updated: 2016-10-17
• Results posted: 2014-10-08

Locations

1 site across 1 country: United States